The Clinical Kinase Index (CKI): A user friendly application to prioritize kinases as prospective cancer drug targets
Rimpi Khurana, Stephan C. Schürer · Software Impacts · 2022
Kinases are among the most established druggable proteins with currently over 50 approved kinase inhibitor drugs, most of them for cancer. However, these drugs only target a small subset of the human kinome and many kinases remain "dark" or "understudied" (Essegian et al. 2020 [1], Oprea et al. 2018 [2]). To improve the utility to evaluate the clinical relevance of kinases, including their potential as novel prospective cancer drug targets, we developed the Clinical Kinase Index (CKI). CKI is an inter interactive web application with harmonized datasets extracted from several resources that allows researchers and clinicians to prioritize and evaluate the clinical relevance of kinases as cancer drug targets across solid.